Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Neoplasms 9Leukemia, Myeloid, Acute 4Leukemia 4Carcinoma 3Myelodysplastic Syndromes 2Hematologic Diseases 2Small Cell Lung Carcinoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1Acute Disease 1

Interventions

nilotinib 50Imatinib Mesylate 48Dasatinib 25bosutinib 18asciminib 17ponatinib 10Homoharringtonine 5Cytarabine 4olverembatinib 3Interferon-alpha 3Decitabine 3tozasertib 2peginterferon alfa-2a 2flumatinib 2fludarabine phosphate 2ON 01910 2Mycophenolic Acid 2Melphalan 2Interferon alpha-2 2Filgrastim 2Cyclophosphamide 2Bone Marrow Transplantation 2BID protein, human 2Azacitidine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2vosaroxin 1troxacitabine 1triciribine 1terameprocol 1sonidegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × vosaroxin × Clear all
NCT00246662 2017-03-30

Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies

Sunesis Pharmaceuticals

Phase 1 Completed
75 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡